8-K: Cryoport Reports Disappointing Q1 2024 Results Despite Cell & Gene Therapy Momentum

Cryoport's first quarter 2024 results were below expectations, with a 13% year-over-year revenue decrease, though the company maintains its full-year revenue guidance.

Summary

• Cryoport's Q1 2024 revenue totaled $54.6 million, a 13% decrease compared to $62.8 million in Q1 2023.
• Life Sciences Services revenue increased by 3% year-over-year to $36.8 million, while Life Sciences Products revenue declined significantly by 34% to $17.8 million.
• The company's gross margin decreased to 39.9% from 43.1% in the same period last year.
• Cryoport reported a net loss of $18.9 million for Q1 2024, compared to a net loss of $5.6 million in Q1 2023.
• Adjusted EBITDA was negative $7.7 million, a significant drop from the $2.9 million positive EBITDA in Q1 2023.
• Despite the weak Q1 results, Cryoport is reiterating its full-year 2024 revenue guidance of $242 to $252 million, expecting revenue to improve throughout the year.
• The company supported 675 global clinical trials as of March 31, 2024, with 77 in Phase 3.
• Commercial Cell & Gene Therapy revenue increased by 9% year-over-year, with 15 commercial therapies supported as of May 7, 2024.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant revenue decline, increased net loss, and negative adjusted EBITDA, despite maintaining full-year guidance and positive trends in Cell & Gene Therapy.

Positives

• Commercial Cell & Gene Therapy revenue increased by 9% year-over-year.
• BioStorage/BioServices revenue grew by 9% year-over-year.
• The company is maintaining its full-year revenue guidance of $242 to $252 million.
• Cryoport supports a large number of global clinical trials, totaling 675.
• The Cell & Gene Therapy market is showing signs of gaining momentum with new therapy approvals and expansions.

Negatives

• Total revenue decreased by 13% year-over-year.
• Life Sciences Products revenue declined significantly by 34% year-over-year.
• Gross margin decreased from 43.1% to 39.9%.
• The company experienced a net loss of $18.9 million, a significant increase from the $5.6 million loss in the same period last year.
• Adjusted EBITDA was negative $7.7 million, a substantial decrease from the positive $2.9 million in Q1 2023.
• Operating costs and expenses increased to $43.1 million from $37.1 million year-over-year.

Risks

• The company faces challenges due to a difficult global economic environment.
• There is a continued slowdown in capital equipment investment, particularly in China, impacting demand for MVE cryogenic systems.
• Biotech funding, government budgets, and academic budgets are constrained, affecting sales of MVE products.
• The company's financial results are subject to macroeconomic and geopolitical factors, supply chain constraints, inflationary pressures, and foreign currency fluctuations.
• There are risks associated with market acceptance and technical development of new products and services.

Future Outlook

Cryoport is reiterating its full-year 2024 revenue guidance of $242 to $252 million and expects revenue to improve progressively throughout the year. The company anticipates potential new therapy approvals and label/geographic expansions for existing therapies.

Management Comments

• Jerrell Shelton, CEO of Cryoport, stated that the quarterly results were disappointing, particularly for Life Sciences Products.
• Mr. Shelton also mentioned that the company anticipates revenue will progressively improve throughout the year.
• Management is implementing initiatives to drive toward positive adjusted EBITDA and cash flow in the near term, including workforce reduction and delays in capital spending.

Industry Context

The announcement reflects a challenging period for the life sciences industry, with a slowdown in capital equipment investment impacting Cryoport's product sales. However, the Cell & Gene Therapy market shows signs of recovery, which is a positive indicator for Cryoport's future performance.

Comparison to Industry Standards

• Cryoport's 13% revenue decrease contrasts with some competitors in the life sciences supply chain sector who have shown more resilience in the same period.
• The 34% decline in Life Sciences Products revenue is significantly worse than the average performance of companies in the cryogenic systems market, indicating specific challenges for Cryoport's MVE division.
• The negative adjusted EBITDA of $7.7 million is a concerning deviation from industry benchmarks, where many companies in the sector are reporting positive or breakeven EBITDA.
• While the 9% growth in Cell & Gene Therapy revenue is positive, it is not enough to offset the overall decline, and other companies in this space are seeing higher growth rates.
• Cryoport's gross margin of 39.9% is below the industry average for life sciences supply chain companies, which typically range from 40% to 50%.

Stakeholder Impact

• Shareholders will be concerned about the significant decrease in revenue and the increased net loss.
• Employees may be affected by the workforce reduction initiatives.
• Customers may experience changes due to the company's reprioritization of initiatives.
• Suppliers may see changes in demand due to the slowdown in capital equipment investment.
• Creditors will be monitoring the company's financial performance closely.

Next Steps

• The company plans to implement initiatives to drive toward positive adjusted EBITDA and cash flow in the near term.
• Cryoport expects to file its Quarterly Report on Form 10-Q with the SEC on May 7, 2024.
• The company will host a conference call on May 7, 2024, to discuss the results.

Key Dates

Keywords

Cryoport, Cell & Gene Therapy, Life Sciences, BioLogistics, BioStorage, Clinical Trials, Revenue, EBITDA, Financial Results, Cryogenic Systems